• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Illumina launches iHope Program for pediatric undiagnosed genetic diseases

Illumina launches iHope Program for pediatric undiagnosed genetic diseases

December 2, 2016
CenterWatch Staff

Illumina has announced the iHope program, a philanthropic initiative aimed at identifying the genetic causes of undiagnosed rare diseases in children. With initial program partners Foundation for the Children of the Californias, Rare Genomics Institute and UCSF Benioff Children’s Hospital San Francisco, selected patients in financial need will receive clinical whole-genome sequencing performed by the Illumina Clinical Services Laboratory. Through whole-genome sequencing—the process of determining the order of all the DNA in a person’s body—Illumina and the iHope program partners strive to end years-long diagnostic odysseys of unnecessary and inconclusive testing for these children and their families.

Under US law, a disease is considered rare if it has a prevalence of fewer than 200,000 affected individuals in the U.S. Global Genes estimates that there are as many 30 million individuals in the US with a rare disease, 80% of which is genetic in origin. The iHope program was created out of an awareness of the challenges facing patients with rare and undiagnosed genetic diseases and their families—many of whom face financial hardship and are not otherwise able to access next-generation sequencing-based testing. Approximately 50% of those affected by rare diseases are children and 30% do not live to be five years old.

“Understanding the scope and size of the population affected by rare diseases, we have a moral imperative to increase the visibility of this global health problem and help find solutions for the children and families who are suffering,” said Illumina President and CEO Francis deSouza. “With precision medicine and large-scale genomic initiatives being launched all over the world, we believe that genomics is reaching an inflection point in the public consciousness. The iHope program aims to build on that public awareness by focusing on the needs of those with rare, undiagnosed genetic diseases and showing how next-generation sequencing can benefit this population.”

“We know that rare diseases can affect any family at any time. Being a part of iHope gives me confidence that together we can make a difference for patients with these conditions,” said Jimmy Lin, M.D., Ph.D., founder and president, Rare Genomics Institute. “Whole-genome sequencing has already shown its value in identifying rare and undiagnosed diseases and, as we learn more, I believe that the process will become a routine part of medical practice. Children will no longer have to suffer through a crusade of testing.”

Clinical experts affiliated with iHope partner institutions will make referrals to the Illumina Clinical Services Laboratory, which is certified under the Clinical Laboratories Improvements Amendments (CLIA) and accredited by the College of American Pathologists (CAP). These experts—including pediatric intensivists, medical geneticists, genetic counselors, and others—will refer children who have financial need and undiagnosed conditions suspected to be of genetic origin.

Eligible program participants selected by the iHope program partners will receive whole-genome sequencing at no cost. Clinical whole-genome sequencing is intended to provide information to physicians to aid in the diagnosis of inherited diseases, and to try to identify the underlying cause of a genetic condition. This test is most appropriate for situations where the evaluation of multiple genes may clarify or refine the diagnosis, a situation that can occur when the presenting set of symptoms and tests are inconclusive, there are many candidate genes to evaluate, or physicians believe that the patient may have multiple genetic conditions.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing